New immunotherapy option for High-Risk pancreatic cancer patients
Disease control
AVAILABLE
This expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 16, 2026 23:49 UTC